Anthropic sets out its biopharma ambitions in IPO doc
The prospectus for Anthropic's IPO, which could take place in November and be the largest-ever listing in the US, has highlighted drug discovery, disease detection, and the delivery of personalised therapy as key benefits that can be delivered using AI in the coming years.
The company, which has been built around its Claude AI model and has already signed up nine of the top 10 big pharma groups to use the platform, originally announced its intention to go public in June and plans to list on the Nasdaq under the ANT symbol.
While Anthropic has not disclosed the number of shares to be released, their price range, or a date for the listing, Renaissance Capital has suggested it could be targeting around $75 billion, which would put it on a par with the SpaceX IPO in June, which took the record as the largest of all time.
"In the life sciences sector, where annual global pharmaceutical spend is expected to exceed $2 trillion in 2026, Claude is used in drug discovery and development by our customers, our biotechnology partners, and our own researchers," said the company in its IPO prospectus.
"We are building AI agents that support scientists at each stage of that process," it added. "To build the best tools for the industry, we have invested in deep life sciences expertise of our own, hiring industry experts, building a molecular biology lab, acquiring Coefficient Bio, and partnering with industry leaders."
Anthropic reported $16.3 billion in revenue in the six months ended 30th June 2026, but that came alongside losses of more than $80.7 billion, and those figures will do little to assuage fears that AI is in an investment bubble – a subject of intense debate among economists and investors with strong arguments on both sides.
It could be the first pure-play AI giant to go public, although rival OpenAI has also said it is planning to do so, so it will be something of a test case for the AI sector.
The prospectus also cites the "catastrophic or existential risks to humanity" posed by AI, particularly if such systems are "misused, replicated, weaponised, or allowed to operate with a high degree of autonomy," while also extolling the potential of "millions of virtual agents with the ability to revolutionise every area of human endeavour."
Other IPO news
In the last few days, biotech companies Aspen Neuroscience and Bambusa Therapeutics also set terms for their previously announced IPOs.
Aspen said it would offer 9.4 million shares at a price range of $15 to $17, which could raise up to $160 million for its portfolio of stem cell therapies for neurodegenerative diseases, headed by sasineprocel, which is in a phase 1/2a trial in Parkinson's.
Bambusa, meanwhile, is offering the same number of shares in its IPO, at the same price range, with the proceeds earmarked for lead product candidate BBT001, a bispecific antibody directed against IL-4Rα and IL-31, which is in early-stage development to treat a type of dermatitis and other inflammatory skin diseases.
